Abstract
Background
Treatment with biologic pharmaceuticals may be associated with an increased risk of immune-mediated disease. Palivizumab is a humanized monoclonal antibody designed to provide passive immunity against respiratory syncytial virus infection. Palivizumab is primarily used in preterm children known to be immunologically immature. The long-term effect of palivizumab in terms of autoimmune diseases has not yet been investigated.
Aim
Our objective was to investigate whether exposure to palivizumab was associated with the development of autoimmune diseases in children.
Methods
This was a population-based cohort study including data from 769,523 Danish children born between 1 January 1999 and 31 December 2010 and data from 581,742 Swedish children born between 1 July 2005 and 31 December 2010.
Results
Of the 1,351,265 children included, 1192 (0.09 %) were exposed to palivizumab. Nine cases of autoimmune disease were diagnosed among palivizumab-exposed children during the period of observation. Among the children exposed to palivizumab, one child in Denmark developed inflammatory bowel disease; in Sweden, children developed juvenile arthritis (one child), diabetes mellitus (two children), celiac disease (four children), and inflammatory bowel disease (one child). The risk of autoimmune disease was not significantly increased after palivizumab exposure (hazard ratio adjusted for age and country: 1.54; 95 % confidence interval 0.80–2.95).
Conclusion
The risk of autoimmune disease was not increased after palivizumab exposure. Given the small number of incident cases of autoimmune disease observed, this finding should be interpreted with caution.
Similar content being viewed by others
References
Committee on Infectious Diseases. From the American Academy of Pediatrics: policy statements—modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009;124(6):1694–701.
Medical Products Agency. http://www.lakemedelsverket.se/malgrupp/Halsosjukvard/Behandlings–rekommendationer/Behandlingsrekommendation—listan/RSV-infektioner/. Accessed 23 Sept 2013.
Diamond B. Systemic autoimmunity, organ-specific autoimmunity. In: Paul W, editor. Fundamental immunology. 5th ed. Philadelphia: Wolters Kluwer Health; 2008. p. 1291–373.
Dillon MJ. Childhood vasculitis. Lupus. 1998;7(4):259–65.
Poddar U. Pediatric and adult celiac disease: similarities and differences. Indian J Gastroenterol. 2013;32(5):283–8.
Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450.
Pedersen CB, Gotzsche H, Moller JO, Mortensen PB. The Danish Civil Registration System. A cohort of eight million persons. Dan Med Bull. 2006;53(4):441–9.
The Swedish National Patient Register. The National Board of Health and Welfare. (Socialstyrelsen) http://www.socialstyrelsen.se/register/halsodataregister/patientregistret/inenglish. Accessed 1 Feb 2015.
Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull. 1999;46(3):263–8.
Gaist D, Sorensen HT, Hallas J. The Danish prescription registries. Dan Med Bull. 1997;44(4):445–8.
Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad OP, Bergman U, et al. The new Swedish Prescribed Drug Register—opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2007;16(7):726–35.
Marsal K, Persson PH, Larsen T, Lilja H, Selbing A, Sultan B. Intrauterine growth curves based on ultrasonically estimated foetal weights. Acta Paediatr. 1996;85(7):843–8.
Brookhart MA, Wyss R, Layton JB, Sturmer T. Propensity score methods for confounding control in nonexperimental research. Circ Cardiovasc Qual Outcomes. 2013;6(5):604–11.
Bhogal N. Immunotoxicity and immunogenicity of biopharmaceuticals: design concepts and safety assessment. Curr Drug Saf. 2010;5(4):293–307.
European Medicines Agency (EMA). Medicines in the pediatric population. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000023.jsp&mid=WC0b01ac05800240cd (2015). Accessed 12 June 2015.
Descotes J, Gouraud A. Clinical immunotoxicity of therapeutic proteins. Expert Opin Drug Metab Toxicol. 2008;4(12):1537–49.
Descotes J. Immunotoxicity of monoclonal antibodies. MAbs. 2009;1(2):104–11.
Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov. 2010;9(4):325–38.
Ramos-Casals M, Roberto PA, Diaz-Lagares C, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev. 2010;9(3):188–93.
Karvonen M, Viik-Kajander M, Moltchanova E, Libman I, LaPorte R, Tuomilehto J. Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group. Diabetes Care. 2000;23(10):1516–26.
Mieli-Vergani G, Vergani D. Autoimmune hepatitis in children. Clin Liver Dis. 2002;6(3):623–34.
Mieli-Vergani G, Vergani D. Autoimmune paediatric liver disease. World J Gastroenterol. 2008;14(21):3360–7.
Riise OR, Handeland KS, Cvancarova M, Wathne KO, Nakstad B, Abrahamsen TG, et al. Incidence and characteristics of arthritis in Norwegian children: a population-based study. Pediatrics. 2008;121(2):e299–306.
Dohoo IR. Bias—is it a problem, and what should we do? Prev Vet Med. 2014;113(3):331–7.
Haerskjold A, Henriksen L, Way S, Malham M, Hallas J, Pedersen L, et al. The Danish National Prescription Registry in studies of a biological pharmaceutical: palivizumab—validation against two external data sources. Clin Epidemiol. 2015;7:305–12.
Linder M, Bystrom C, Kieler H, Bergman G, Haerskjold A. Use of palivizumab is underestimated in the Swedish Prescribed Drug Register—implications for register-based drug studies. Clin Epidemiol. 2015;7:45–51.
Author contributions
LGS was responsible for the overall study and wrote the protocol together with HR and HK. HR supervised the statistical analyses of the Danish data and the combined Danish and Swedish data. ML was responsible for the statistical analyses in Sweden. AH collected data, participated in the data management and data analyses, and wrote the draft manuscript. SFT took part in the procedure to define the autoimmune diseases under study. LH performed data management in Denmark on the Danish data and the combined Danish and Swedish data. All authors read and approved the final manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
The study was an investigator-driven study funded by AbbVie. A scientific review was provided by AbbVie, but all decisions regarding the study design, the statistical analyses, and the manuscript were made by the authors.
Funding
AbbVie provided a research grant to Karolinska Institute in Sweden and Rigshospitalet in Denmark. The wages of Ann Haerskjold, Lonny Henriksen, and Henrik Ravn were paid by a grant from AbbVie. Marie Linder, Simon Francis Thomsen, Helle Kieler, Lone Graff Stensballe have no financial relationships relevant to this article.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Haerskjold, A., Linder, M., Henriksen, L. et al. Palivizumab Exposure and the Risk of Autoimmune Disease: A Cross-National Cohort Study. Pediatr Drugs 18, 435–441 (2016). https://doi.org/10.1007/s40272-016-0191-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40272-016-0191-3